Clinical trials: Non-small Cell Lung Carcinoma
Squamous Non-Small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic…
- Trial name
- NCT02106546
- Testing
- Carboplatin, Veliparib, Paclitaxel
- Where
- 225 sites in United States, Australia and 36 more
- Volunteers
- 970 people
- Sponsor
- AbbVie
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
This phase Ib trial studies the side effects of pembrolizumab and trametinib in treating patients with non-small cell lung cancer and KRAS gene mutations that has spread to other places in the body.
- Conditions
- KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03299088
- Testing
- Pembrolizumab, Trametinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonathan Riess
Lung Cancer, Lung Neoplasms
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring.
- Conditions
- Lung Cancer, Lung Neoplasms, Cancer of Lung, Cancer of the Lung
- Trial name
- NCT02370303
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Conditions
- Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung
- Trial name
- SUNRISE (NCT01999673)
- Testing
- bavituximab, Docetaxel
- Where
- 161 sites in United States, Australia and 12 more
- Volunteers
- 582 people
- Sponsor
- Peregrine Pharmaceuticals
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc
Leptomeningeal Metastasis
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
Intrathecal chemotherapy is one of the mainstay treatment options for leptomeningeal metastases. Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT06304441
- Testing
- Osimertinib, Pemetrexed
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangzhou Medical University
Lung Cancer
Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer
RATIONALE: Surgical removal of all lymph nodes in the chest may kill cancer cells that have spread from tumors in the lung. It is not yet known whether complete removal of all lymph nodes in the chest is more effective than…
- Trial name
- NCT00003831
- Testing
- conventional surgery
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 1,023 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer.
- Trial name
- NCT01281124
- Testing
- Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Non Small Cell Lung Cancer
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
- Conditions
- Cancer, Non Small Cell Lung Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT01000896
- Testing
- AZD0530, Carboplatin, paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
- Trial name
- MAP (NCT07316062)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.
- Trial name
- NCT00112346
- Testing
- Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
- Where
- 38 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00425646
- Testing
- bevacizumab, imatinib mesylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Metastatic Non-small Cell Lung Cancer (NSCLC)
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.
- Trial name
- NCT03158883
- Testing
- Avelumab, Stereotactic ablative radiotherapy (SAR)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Megan Daly, MD
Non-Small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)
Bone-marrow-derived progenitor cells (EPCS) play an important role in neovascularization and tumor growth. In lung cancer, angiogenesis is an important event in mechanisms of tumor proliferation and metastasis.
- Trial name
- CBNPC:PCE (NCT00826683)
- Testing
- Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Non Small Cell Lung Cancer
Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer
The goal of this observational study is compared the perioperative outcomes of robotic lobectomy using the SP system via the subcostal approach with those of multi-port robotic lobectomy using the Xi system via the intercostal…
- Trial name
- SP vs MP robot (NCT07099105)
- Where
- South Korea
- Volunteers
- 339 people
- Sponsor
- Korea University Guro Hospital
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy.
- Conditions
- Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
- Trial name
- NCT05616624
- Testing
- ADI-PEG 20, Gemcitabine, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of hypofractionated proton beam radiation therapy when given together with paclitaxel and carboplatin in treating patients with stage II-III non-small cell lung cancer.
- Trial name
- NCT02172846
- Testing
- Proton beam radiation therapy (PBT), Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03910127
- Testing
- TQB2450, Anlotinib
- Where
- 3 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Thymic Carcinoma, Non-small Cell Lung Cancer
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint…
- Conditions
- Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
- Trial name
- NCT03583086
- Testing
- Vorolanib, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
This phase III trial studies how well a telehealth self-management program works in improving survivorship care and outcomes in stage I-III non-small cell lung cancer or colorectal cancer survivors.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT04428905
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Survivorship Care Plan
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.